Gender, Obesity, C-Reactive Protein, and Oxidative Stress - Full Text View

Purpose

This randomized placebo-controlled trial will test whether supplementing with vitamins C and E can lower markers of inflammation and oxidative stress in healthy adults. We will examine whether one antioxidant vitamin is more effective than another, and whether gender or body fat influence the treatment effects. We will also determine whether gender, body fat, or menopausal status are associated with baseline concentrations of inflammation and oxidative stress markers.

Condition	Intervention
Cardiovascular Disease	Dietary Supplement: Vitamin C Dietary Supplement: Vitamin E Dietary Supplement: Placebo

MedlinePlus related topics:

Dietary Supplements Obesity Stress

ChemIDplus related topics:

Vitamin E alpha-Tocopherol alpha-Tocopheryl acetate Tocopherols Ascorbic acid

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Efficacy Study

Further study details as provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):

Primary Outcome Measures:

Change in high-sensitivity C-reactive protein (hsCRP) [ Time Frame: 8-week intervention ]

Secondary Outcome Measures:

Change in blood pressure [ Time Frame: 8-week intervention ]
Change in self-reported stress and psychosocial factors [ Time Frame: 8-week intervention ]
Change in oxidative stress biomarkers (F2-Isoprostanes, malondialdehyde) [ Time Frame: 8-week intervention ]
Association of gender, body fat, menopausal status with baseline concentrations of inflammation and oxidative stress biomarkers. [ Time Frame: Baseline ]

Enrollment:	396
Study Start Date:	April 2004

Arms	Assigned Interventions
X: Experimental	Dietary Supplement: Vitamin C 1000 mg/day
Y: Experimental	Dietary Supplement: Vitamin E 800 IU/day
Z: Placebo Comparator	Dietary Supplement: Placebo

Detailed Description:

Participants will be given 1000 mg vitamin C or 800 IU vitamin E daily for 60 days.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion criteria:

Nonsmoker and not passively exposed
Males and females 18 year and older
Able to take vitamin supplements
Able to take acetominophen instead of aspirin or NSAIDs during the study

Exclusion criteria:

Pregnancy or lactation
History of ever smoking or passive smoke exposure in the last year
Active liver disease; history of HIV/AIDS, diabetes, kidney stones, hemochromatosis, or autoimmune diseases; heart disease, stroke, or cancer in the last 5 years
User of prescribed anti-inflammatory or lipid-lowering medications, oral contraceptives, hormone replacement therapy, or blood-thinning drugs
User of iron supplements or vitamin E at 600 IU per day or more
Consumption of more than 2 alcoholic beverages per day

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00079963

Locations


United States, California
	University of California, Berkeley School of Public Health
	Berkeley, California, United States, 94720-7360

Sponsors and Collaborators

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Investigators


Principal Investigator:	Gladys Block, Ph.D.	University of California at Berkeley

More Information

Publications indexed to this study:

Block G, Jensen CD, Morrow JD, Holland N, Norkus EP, Milne GL, Hudes M, Dalvi TB, Crawford PB, Fung EB, Schumacher L, Harmatz P. The effect of vitamins C and E on biomarkers of oxidative stress depends on baseline level. Free Radic Biol Med. 2008 Aug 15;45(4):377-84. Epub 2008 Apr 16.

Study ID Numbers:	62378DK
First Received:	March 18, 2004
Last Updated:	October 19, 2007
ClinicalTrials.gov Identifier:	NCT00079963
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Tocopherols

Obesity

Tocopherol acetate

Vitamin E

Stress

Ascorbic Acid

Alpha-Tocopherol

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on October 10, 2008

Sponsored by:	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by:	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier:	NCT00079963